Abstracts tagged "autoantibodies and rheumatoid arthritis (RA)"

Abstract Number: 3103 • 2015 ACR/ARHP Annual Meeting
Carbamylated Human Albumin Is One of the Target Antigens of Anti-Carbamylated Protein Antibodies
Shuichiro Nakabo¹, Koichiro Ohmura¹, Kosaku Murakami¹, Ran Nakashima¹, Moritoshi Furu², Masahiro Ishikawa², Motomu Hashimoto², Yoshitaka Imura¹, Naoichiro Yukawa¹, Hajime Yoshifuji¹, Hiromu Ito², Takao Fujii² and Tsuneyo Mimori^1,2, ¹Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Anti-carbamylated protein antibody (anti-CarP) is seen in 45% of rheumatoid arthritis (RA) patients [1]. The precise target antigen (Ag) of anti-CarP had not been…
Abstract Number: 3154 • 2015 ACR/ARHP Annual Meeting
The Importance of Somatic Hypermutation for the Immunoreactivity Towards Neutrophil Extracellular Traps (NETs)-Citrullinated Autoantigens of RA Synovial Monoclonal Antibodies
Elisa Corsiero¹, Emanuela Carlotti², Costantino Pitzalis³ and Michele Bombardieri⁴, ¹WHRI - EMR, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, ³Centre for Experimental Medicine & Rheumatology, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom
Background/Purpose: We previously showed that anti-citrullinated peptide/protein antibodies (ACPA) targeting citrullinated antigens contained in neutrophils extracellular traps (NETs) can be manufactured within ectopic germinal center-like…
Abstract Number: 446 • 2014 ACR/ARHP Annual Meeting
Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-Risk for Future Rheumatoid Arthritis
Gregory M. Ingolia¹, M. Kristen Demoruelle², Mark C. Parish², Ryan W. Gan³, Jason R. Kolfenbach², Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁸, Richard M. Keating⁹, Alvin Yee¹⁰, Michael Mahler¹⁰, Jill M. Norris³, Kevin D. Deane² and V. Michael Holers¹¹, ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Scripps Clinic, La Jolla, CA, ¹⁰Research, INOVA Diagnostics, San Diego, CA, ¹¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose Immunoglobulin A (IgA) autoantibodies (Abs) to citrullinated proteins (ACPAs) are present in the preclinical period of RA development, a finding that suggests a mucosal…
Abstract Number: 357 • 2014 ACR/ARHP Annual Meeting
Development and Validation of a Diagnostic Bead-Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect “Seronegative” Rheumatoid Arthritis
Stefan Vordenbäumen¹, Angelika Lueking², Carmen Theek², Ralph Brinks¹, Rebecca Fischer-Betz¹, Jutta Richter¹, Ellen Bleck¹, Jacqueline Detert³, Gerd Burmester⁴, Peter Schulz-Knappe² and Matthias Schneider¹, ¹Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ²Protagen AG, Dortmund, Germany, ³Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁴Departement of Rhe, University Medicine, Berlin, Germany
Background/Purpose: Autoantibodies (auto-Ab) against citrullinated peptides (ACPA) and rheumatoid factor (RF) are important biomarkers in the diagnostic process of rheumatoid arthritis (RA). However, RF or…
Abstract Number: 2302 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibody In Japanese Patients With Rheumatoid Arthritis
Shunichi Shiozawa¹, Leendert A. Trouw² and Kazuko Shiozawa³, ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³The Rheumatic Diseases Center, Konan Kakogawa Hospital, Kakogawa, Japan
Background/Purpose: Serology represents a powerful tool for the identification and sub-classification of patients with rheumatoid arthritis (RA). IgM-rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies…
Abstract Number: 909 • 2013 ACR/ARHP Annual Meeting
Diagnostic Autoantibody Signatures Of Rheumatoid Arthritis Patients Identified With a Bead-Based Assay Approach
Angelika Lueking¹, Petra Budde¹, Stefan Vordenbäumen², Carmen Theek¹, Heike Goehler¹, Martin Gamer¹, Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease typically characterized by chronic inflammation, accumulation of self-reactive B-cells and production of autoantibodies of which anti–cyclic citrullinated…
Abstract Number: 912 • 2013 ACR/ARHP Annual Meeting
B-Cell Responses To De Novo Identified Citrullinated Fibrinogen Peptides Are Associated With PTPN22 Risk Allele
Vijay Joshua¹, Loes Schobers², Lena Israelsson³, Johan Rönnelid⁴, Monika Hansson⁵, Anca I Catrina⁶, Ger JM Pruijn² and Vivianne Malmström⁷, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Biomolecular Chemistry, Radboud University, Nijmegen, Netherlands, ³Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies against citrullinated proteins are common in patients with rheumatoid arthritis (RA) and appear prior to the onset of the disease [1]. Many of…
Abstract Number: 869 • 2013 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibodies Are Present Prior To The Diagnosis Of Rheumatoid Arthritis and Predict Future Disease Onset
Ryan W. Gan¹, Leendert A. Trouw², Jing Shi², René E.M. Toes², Tom W. J. Huizinga², Gary O. Zerbe³, Kevin D. Deane⁴, Jess Edison⁵, William R. Gilliland⁶, Jill M. Norris¹ and V. Michael Holers⁷, ¹Epidemiology, Colorado School of Public Health, Aurora, CO, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁵Department of Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Anti-cyclic citrullinated peptide-2 (CCP2) can be present in serum years before a diagnosis of rheumatoid arthritis (RA), and is highly specific (>95%) for the…
Abstract Number: 1771 • 2012 ACR/ARHP Annual Meeting
Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis
Jing Shi¹, Lotte van de Stadt², Nivine Levarht³, T.W.J. Huizinga⁴, R. E. M. Toes⁴, Leendert A. Trouw⁵ and Dirkjan van Schaardenburg², ¹Rheumatology, LUMC, Leiden, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Centre, Leiden, Netherlands
Background/Purpose: Recently, we discovered a new autoantibody system in rheumatoid arthritis (RA): anti carbamylated protein antibodies (anti-CarP). These antibodies have additional prognostic value in predicting…
Abstract Number: 1194 • 2012 ACR/ARHP Annual Meeting
Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations
Elizabeth D. Ferucci¹, Irene Smolik², Tammy L. Choromanski³, David B. Robinson⁴, Marianna M. Newkirk⁵, Marvin J. Fritzler⁶, Antony Rosen⁷, Erika Darrah⁸ and Hani S. El-Gabalawy⁴, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ³Alaska Native Tribal Health Consortium, Anchorage, AK, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵Medicine, McGill University Health Centr, Montreal, QC, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸Division of Rheumatology, The Johns Hopkins University, Baltimore, MD
Background/Purpose: Antibodies directed against peptidylarginine deiminase type 4 (PAD-4) are present in a subset of patients with rheumatoid arthritis (RA) and are associated with more…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].